Sean Dalziel supports Ridgeback with executive leadership for all aspects of CMC for
molnupiravir including technology transfer from Emory University DRIVE, through to
establishing the initial global supply chain and strategy. Sean has worked collaboratively to facilitate the transfer of all molnupiravir manufacturing responsibilities to Merck.
Sean Dalziel is Managing Director and Co-founder of Cleo Life Sciences, a specialty consultancy and product innovation firm located within JLABS, South San Francisco. Sean is a pharmaceutical executive and entrepreneur with 25 years of industry experience in chemistry, manufacturing, and controls (CMC), technical operations, product development, and corporate development/strategy. Through Cleo Life Sciences, Sean provides executive consultant roles at multiple biopharmaceutical companies and research services to prototype pharmaceutical drug products and process. Sean has supported CMC aspects of over 35 discovery through clinical stage programs, including 6 now in registration trials, and 4 commercial products: Kyprolis ® , Vibativ ® , Oxbryta ® , and Yupleri ® . He has therapeutic area experiences across oncology, hematology, antivirals, antibiotics, auto-immune, allergic reactions, GI, liver, and lung diseases. Sean previously was Head of Technical Operations / CMC at Tobira Therapeutics, Onyx Pharmaceuticals, and roles of increasing responsibilities at Theravance, DuPont, and CSIRO. Sean’s academic qualifications include PhD in Chemical Engineering from the University of Queensland, MBA from UC Berkeley, Bachelor of Applied Science Honors from University of Western Sydney, Bachelor of Science in Chemistry and Molecular Biology from the University of Sydney.
Outside of work, Sean loves spending time with his wife Gena and children Mark and Josie. For fun, Sean enjoys flying aircraft, surfing, fishing, and snowboarding.